Moreover, although the tumor burden was substantially increased in the IL-33-expressing glioma compared to the IL-33-negative tumors, the actual size of the tumor suggests that the clinical criteria for endpoint were not reached exclusively due to tumor burden. The gene discussed is IL33; the disease is central nervous system cancer.